A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia

American Journal of Medicine

Volumn 104, Issue 2, 1998, Pages 137-143

  McKenney, James M ^a,f   McCormick, Lisa S ^b   Weiss, Stuart ^c   Koren, Michael ^d   Kafonek, Stephanie ^e   Black, Donald M ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c S Diego Endocr and Medical Clinic   (United States)

^d Clinic Jacksonville   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f National Clinical Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; NIACIN; PYRROLES; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 0032004986     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00311-2     Document Type: Article

References (42)

1. 1. Friedewald WT. Epidemiology of cardiovascular disease. In: Wyngaarden JB, Smith Jr LH, Bennett JC, eds. Cecil Textbook of Medicine. Philadelphia: WB Saunders; 1992:151-155.
2. 2. Ross R. The pathogenesis of atherosclerosis. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders; 1992:1106-1124.
3. 3. Thompson GR, ed. A Handbook of Hyperlipidemia. London: Current Science; 1990:69-85, 177-194.
4. 4. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. NEJM. 1980;302:1383-1389.
5. 5. Carlson LA, Bottiger LE. Risk factors for ischemic heart disease in men and women. Results of the 19-year follow-up of the Stockholm Prospective Study. Acta Med Scand. 1985;218:207-211.
6. 6. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J. 1986;112:432-437.
7. 7. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb Vasc Biol. 1991;11:2-14.
8. 8. National Institute of Health Consensus Development Panel. Triglyceride, high-density lipoprotein, and coronary heart disease. Consensus Statement. 1992;10:1-28.
9. 9. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
10. 10. European Atherosclerosis Society. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis. 1992;2:113-156.
11. 11. Drood JM, Zimetbaum PJ, Frishman WH. Nicotinic acid for the treatment of hyperlipoproteinemia. J Clin Pharmacol. 1991;31(7): 641-650.
12. 12. Berge KG, Achor RWP, Christensen NA, et al. Hypercholesterolemia and nicotinic acid. Am J Med. 1961;31:24-35.
13. 13. Keenan JM, Fontaine PL, Wenz JB, et al. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991;151:1424-1432.
14. 14. McKenney JM, Proctor JC, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271:672-677.
15. 15. Jungnickel PW, Maloley PA. Comment: adverse-effect profile of sustained-release niacin. DICP Ann Pharmacother. 1991;25:1014. Letter.
16. 16. Henkin Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-released niacin. JAMA. 1990;264:241-243.
17. 17. Etchason JA, Miller TD, Squires RW, et al. Niacin-induced hepatitis: a potential side-effect with low dose time-release niacin. Mayo Clin Proc. 1991;66:23-28.
18. 18. Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med. 1989;111:253-255.
19. 19. Abbate SL, Brunzell JD. Pathophysiology of hyperlipidemia in diabetes mellitus. J Cardiovasc Pharm. 1990:16(suppl):S1-7.
20. 20. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J. 1986;112:432-437.
21. 21. Castelli WP. The role of plasma lipids as predictors of risk for coronary heart disease. Drugs. 1990;40(suppl):1-6.
22. 22. Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs. 1996; 51(3):433-459.
23. 23. Plosker GL, McTavish D. Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs. 1995;50(2):334-363.
24. 24. Henwood JM, Heel RC. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs. 1988;36(4):429-454.
25. 25. Haria M, McTavish D. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs. 1997;53(2):299-336.
26. 26. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Vasc Biol. 1995;15:678-682.
27. 27. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor in patients with hypertriglyceridemia. JAMA. 1996;275:128-133.
28. 28. Remmell PS, Gorder DD, Hall Y, Tillotson JL. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). J Am Diet Assoc. 1980;76:351-356.
29. 29. Manual of laboratory operations lipid research clinics program. In: Hainline A, Karon J, Lippel K, eds. Lipids and Lipoprotein Analysis. 2nd ed. Bethesda, Md: National heart, Lung, and Blood Institute, National Institutes of Health; 1982:5.
30. 2+ precipitation procedure for quantitation of high density-lipoprotein cholesterol. Clin Chem. 1982;28:1379-1388.
31. 31. Vacek JL, Dittmeier G, Chiarelli T, et al. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardio. 1995;76(3):182-184.
32. 32. Tsalamandris C, Panagiotopoulos S, Sinha A, et al. Complimentary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and nondiabetic patients. J Cardiovasc Risk. 1994;1(3):231-239.
33. 33. Oster G, Borok GM, Menzin J, et al. Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med. 1996;156(7):731-739.
34. 34. Davignon J, Roederer G, Motigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 1994;73(5):339-345.
35. 35. Davidson MM, McKenney JM, Stein EA, et al, for the Atorvastatin Study Group I. Comparison of 1-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1475-1481.
36. 36. Bertolini S, Bitollo Bon G, et al. The efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997;130:191-197.
37. 37. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, 1-year study comparing safety and efficacy of atorvastatin and simvastatin in patients with hypercholesterolemia. Am J Cardio. 1997; 80:39-44.
38. 38. Carlson LA, Olsson AG, Ballantyne D. On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemia in type IV and type V hyperlipoproteinaemias. Atherosclerosis. 1977;26:603-609.
39. 39. Tornvall P, Hamsten A, Johansson J, Carlson LA. Normalization of the composition of very low density lipoprotein in hypertriglyceridemia by nicotinic acid. Atherosclerosis. 1990;84:219-227.
40. 40. Carlson LA, Hamsten, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
41. 41. Fieseler HG, Armstrong VW, Wieland E, et al. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor pravastatin: results of a 2-year investigation. Clin Chim Acta. 1991;204(1-3):291-300.
42. 42. Slunga L, Johnson O, Dahlen GH. Changes in Lp (a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin. Eur J Clin Pharmacol. 1992;43(4):369-373.